Chemotherapy-Induced peripheral neuropathy in pediatric cancer patients

Seminars in Pediatric Neurology

Volumn 19, Issue 1, 2012, Pages 9-17

  Gilchrist, Laura ^a,b  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^b ST CATHERINE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYTARABINE; IXABEPILONE; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THALIDOMIDE; VINCRISTINE; VINDESINE; VINFLUNINE;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ARM WEAKNESS; AUTONOMIC NEUROPATHY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CEREBELLUM DISEASE; CHILDHOOD CANCER; CLINICAL ASSESSMENT; DRUG DNA BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; LEUKEMIA; LEUKEMIA RELAPSE; LEUKOENCEPHALOPATHY; LIVER CELL CARCINOMA; MEDULLOBLASTOMA; MOTOR NEUROPATHY; MULTIPLE MYELOMA; MUSCLE ATROPHY; NEUROPATHIC PAIN; NEUROTOXICITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; RADICULOPATHY; RARE DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSORY NEUROPATHY; SOLID TUMOR; SPINAL CORD LESION;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84861519297     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2012.02.011     Document Type: Review

References (79)

1. Ries L.A., Smith M.A., Gurney J.G., et al. Cancer incidence and survival among children and adolescents: United states SEER Program 1975-1995. NIH Pub. No. 99-4649 1999, National Cancer Institute, SEER Program, Bethesda, MD.
2. Armstrong T., Almadrones L., Gilbert M.R. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005, 32:305-311.
3. Argyriou AA, Bruna J, Marmiroli P, et al: Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol (in press).
4. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006, 24:1633-1642.
5. Chaudhry V., Cornblath D.R., Polydefkis M., et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008, 13:275-282.
6. Macfarlane B.V., Wright A., Benson H.A. Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. J Pharm Pharmacol 1997, 49:97-101.
7. Silva A., Wang Q., Wang M., et al. Evidence for direct axonal toxicity in vincristine neuropathy. J Peripher Nerv Syst 2006, 11:211-216.
8. Dougherty P.M., Cata J.P., Burton A.W., et al. Dysfunction of multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with vincristine-induced pain. J Pain Symptom Manage 2007, 33:166-179.
9. Gilchrist L.S., Tanner L., Hooke M.C. Measuring chemotherapy-induced peripheral neuropathy in children: Development of the Ped-mTNS and pilot study results. Rehabil Oncol 2009, 27:7-15.
10. Bennouna J., Delord J.P., Campone M., et al. Vinflunine: A new microtubule inhibitor agent. Clin Cancer Res 2008, 14:1625-1632.
11. McDonald E.S., Randon K.R., Knight A., et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity. Neurobiol Dis 2005, 18:305-313.
12. Meijer C., de Vries E.G., Marmiroli P., et al. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999, 20:883-887.
13. Gregg R.W., Molepo J.M., Monpetit V.J., et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphological evidence of toxicity. J Clin Oncol 1992, 10:795-803.
14. Podratz J.L., Knight A.M., Ta L.E., et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011, 41:661-668.
15. Raymond E., Faivre S., Woynarowski J.M., et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998, 25(suppl 5):4-12.
16. Argyriou A.A., Ploychronopoulos P., Iconomou G., et al. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008, 34:368-377.
17. Park S.B., Krishnan A.V., Lin C.S., et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 2008, 15:3081-3094.
18. Argyriou A.A., Koltzenburg M., Polychronopoulos P., et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008, 66:218-228.
19. Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 2007, 1168:46-59.
20. Chou T.C., Zhang X.G., Balog A., et al. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 1998, 95:964-967.
21. Casafont I., Berciano M.T., Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010, 7:167-178.
22. Landowski T.H., Megli C.J., Nullmeyer K.D., et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-34/bortezomib) cytotoxicity in melanoma cell lines. Cancer Res 2005, 65:3828-3836.
23. Montagut C., Rovira A., Albanell J. The proteaosome: A novel target for anticancer therapy. Clin Transl Oncol 2006, 8:313-317.
24. Cata J.P., Weng H.R., Burton A.W., et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007, 8:296-306.
25. Verstappen C.C., Heimans J.J., Hoekman K., et al. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003, 63:1549-1563.
26. Verstappen C.C., Koeppen S., Heimans J.J., et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005, 64:1076-1077.
27. Hartman A., van den Bos C., Stijnen T., et al. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine. Cancer 2006, 106:1395-1401.
28. Dimopoulos M.A., Mateos M.V., Richardson P.G., et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study. Eur J Haematol 2011, 86:23-31.
29. Lanzani F., Mattavelli L., Frigeni B., et al. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst 2008, 13:267-274.
30. Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337-340.
31. Argyriou A.A., Polychronopoulous P., Koutras Iconomou G., et al. Is advanced age associated with increased incidence and severity of chemotherapy induced peripheral neuropathy?. Support Care Cancer 2006, 14:223-229.
32. Chaudhry V., Rowinsky E.K., Sartorius S.E., et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 1994, 35:304-311.
33. Verstappen C.C., Postma T.J., Hoekman K., et al. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer. J Neuro Oncol 2003, 63:201-205.
34. Gustavsson A., Osterman B., Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 2003, 42:605-619.
35. Common Terminology Criteria for Adverse Events. Version 4.03, DCTD, NCI, NIH, DHHS, 2010 Cancer Therapy Evaluation Program, Accessed January 23, 2011. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
36. Postma T.J., Heimans J.J., Muller M.J., et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739-744.
37. Cornblath D.R., Chaudhry V., Carter M.S., et al. Total neuropathy scale: Validation and reliability study. Neurology 1999, 53:1660-1664.
38. Cavaletti G., Bogliun G., Marzorati L., et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 2003, 61:1297-1300.
39. Cavaletti G., Jann S., Pace A., et al. Multi-center assessment of the total neuropathy scale for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006, 11:135-141.
40. Wampler M.A., Miaskowski C., Hamel K., et al. The modified total neuropathy score: A clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol 2006, 4:9-16.
41. Gilchrist LS, Tanner LT. Reliability and validity of the pediatric modified Total Neuropathy Scale (ped-mTNS) for use in children and adolescents ages 5-18. Submitted for the MASCC/ISOO 2012 International Symposium, February 4, 2012.
42. Wampler M.A., Topp K.S., Miaskowski C., et al. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil 2007, 88:1002-1008.
43. Cavaletti G., Frigeni B., Lanzani F., et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-common toxicity scale. J Peripher Nerv Syst 2007, 12:210-215.
44. Anghelescu D.L., Faughnan L.G., Jeha S., et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Periatr Blood Cancer 2011, 57:1147-1153.
45. McGrath P.J., Walco G.A., Turk D.C., et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain 2008, 9:771-783.
46. Calhoun E.A., Welshman E.E., Chang C.H., et al. Psychometric evaluation of the functional assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003, 13:741-748.
47. Sasane M., Tencer T., French A., et al. Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: A review. J Support Oncol 2010, 8:e15-e21.
48. Varni J.W., Burwinkle T.M., Katz E.R., et al. The PedsQL in pediatric cancer: Reliability and validity of the pediatric quality of life inventory generic core scales, multidimensional fatigue scale, and cancer module. Cancer 2002, 94:2090-2106.
49. Albers J., Chaudhry V., Cavaletti G., et al. Interventions for neuropathy caused by cisplatin and related compounds. Cochrane database Syst Rev 2011, 2:CD005228.
50. Koeppen S., Verstappen C.C., Körte R., et al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 2004, 130:153-160.
51. DeAngelis L.M., Gnecco C., Taylor L., et al. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 1991, 67:2241-2246.
52. Stubblefield M.D., Vahdat L.T., Balmaceda C.M., et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol (R Coll Radiol) 2005, 17:271-276.
53. Maestri A., De Pasquale Ceratti A., Cundari S., et al. A pilot study of the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005, 91:135-138.
54. Argyriou A.A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 2005, 64:26-31.
55. Argyriou A.A., Chroni E., Koutras A., et al. Preventing paclitaxel-induced peripheral neuropathy: A phase II trial of vitamin E supplementation. J Pain Symptom Manage 2006, 32:237-244.
56. Kottschade L.A., Sloan J.A., Mazurczak M.A., et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a phase III clinical trial. Support Care Cancer 2011, 19:1769-1777.
57. Moore R.A., Wiffen P.J., Derry S., et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011, 16. CD007938.
58. Ross J.R., Goller K., Hardy J., et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: A prospective, open-label study. J Palliat Med 2005, 8:1118-1126.
59. Rao R.D., Michalak J.C., Sloan J.A., et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110:2110-2118.
60. Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) Accessed March 6, 2012. http://clinicaltrials.gov/ct2/show/NCT01506453.
61. Vondracek P., Oslejskova H., Kepak T., et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol 2009, 13:332-336.
62. Quilici S., Chancellor J., Lothgren M., et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol 2009, 9:6.
63. Rodríguez M.J., Díaz S., Vera-Llonch M., et al. Cost-effectiveness analysis of pre-gabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007, 23:2585-2596.
64. Stubblefield M.D., Burstein H.J., Burton A.W., et al. NCCN task force report: Management of neuropathy in cancer. J Nat Comp Cancer Network 2009, 7(suppl 5):S1-S26.
65. Yang YH, Lin JK, Chen WS, et al: Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study. Support Care Cancer (in press).
66. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007, 132:237-251.
67. Wright M.J., Galea V., Barr R.D. Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther 2005, 85:782-790.
68. Marchese V.G., Chiarello L.A., Lange B.J. Effects of physical therapy intervention for children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2004, 42:127-133.
69. Reinders-Messelink H.A., Schoemaker M.M., Snijders T.A., et al. Analysis of handwriting of children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 2001, 37:393-399.
70. Reinders-Messelink H.A., Schoemaker M.M., Hofte M., et al. Fine motor and handwriting problems after treatment for childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1996, 27:551-555.
71. Attal N., Bouhassira D., Gautron M., et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain 2009, 144:245-252.
72. Park S.B., Lin C.S., Krishnan A.V., et al. Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve 2011, 43:367-374.
73. Cavaletti G., Bogliun G., Marzorati L., et al. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Ann Oncol 2004, 15:1439-1442.
74. Ramchandren S., Leonard M., Mody R.J., et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 2009, 14:184-189.
75. Ness K.K., Hudson M.M., Pui C.H., et al. Signs and symptoms of peripheral neuropathy in adult survivors of childhood acute lymphoblastic leukemia (ALL): Associations with physical performance and chemotherapy doses. Presented at The 11th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, Williamsburg, VA June 2010, 11-12.
76. Ness K.K., Hudson M.M., Pui C.H., et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: Associations with physical performance and chemotherapy doses. Cancer 2011, 113:828-838.
77. Florin T.A., Fryer G.E., Miyoshi T., et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: A report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2007, 16:1356-1363.
78. Ness K.K., Armenian S.H., Kadan-Lottick N., et al. Adverse effects of treatment in childhood acute lymphoblastic leukemia: General overview and implications for long-term cardiac health. Expert Rev Hematol 2011, 4:185-197.
79. Ness K.K., Mertens A.C., Hudson M.M., et al. Limitations on physical performance and daily activities among long-term survivors of childhood cancer. Ann Intern Med 2005, 143:639-647.